Express News | Results of Novocure’s Metis Phase 3 Clinical Trial for Patients With Brain Metastasis From Non-Small Cell Lung Cancer to Be Presented as Late-Breaking Abstract at Asco 2024
Moomoo 24/7Apr 24 10:45 ET
Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler
Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler
Dow JonesApr 10 09:05 ET
Express News | Piper Sandler Reiterates Overweight on NovoCure, Raises Price Target to $28
Moomoo 24/7Apr 10 08:55 ET
Is NovoCure (NASDAQ:NVCR) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Simply Wall StApr 8 13:49 ET
Express News | Novocure Reports 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, At AACR Annual Meeting 2024
Moomoo 24/7Apr 5 07:01 ET
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
BenzingaApr 3 13:35 ET
Novocure Is Maintained at Overweight by Wells Fargo
Novocure Is Maintained at Overweight by Wells Fargo
Dow JonesApr 3 12:53 ET
Express News | Wells Fargo Maintains Overweight on NovoCure, Lowers Price Target to $42
Moomoo 24/7Apr 3 12:43 ET
NVCR, SBNY and VITL Are Among After Hour Movers
Seeking AlphaApr 1 17:08 ET
Trending Stocks Today: MSP Recovery Surges 88.9% Post-Market
April 1st - US stocks trending post-market.Gainers: $MSP Recovery(LIFW.US)$ shoots up 88.9% to $1.26 with a turnover of $5.13 million. Losers: $Gritstone Bio(GRTS.US)$ plummets 35.31% to $1.52 with a
moomoo NewsApr 1 17:05 ET
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
Yahoo FinanceApr 1 12:00 ET
Press Release: Novocure to Report First Quarter 2024 Financial Results
Novocure to Report First Quarter 2024 Financial Results ROOT, Switzerland--(BUSINESS WIRE)--April 01, 2024-- Novocure (NASDAQ: NVCR) announced today that it will report financial results for the fir
Dow JonesApr 1 07:00 ET
Novocure to Report First Quarter 2024 Financial Results
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets
NovocureApr 1 00:00 ET
Why NovoCure Stock Soared 18.3% This Week
Shares of Novocure (NVCR 6.76%) jumped 18.3% this week, according to data from S&P Global Market Intelligence, after the company announced encouraging results from a phase 3 study of its Tumor Treating Fields (TTFields) therapy for treating brain metastases from non-small-cell lung cancer.
The Motley FoolMar 30 06:34 ET
NovoCure's TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed With Raised Price Target
TipRanksMar 29 03:06 ET
Why Novocure Stock Is Jumping Today
The Motley FoolMar 28 11:50 ET
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
TipRanksMar 28 05:01 ET
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
5 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates their recent ra
BenzingaMar 27 16:01 ET
Express News | HC Wainwright & Co. Maintains Neutral on NovoCure, Raises Price Target to $24
Moomoo 24/7Mar 27 13:44 ET
NovoCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 57.17% HC Wainwright & Co. $22 → $24 Maintains Neutral 03/19/2024 11.33% JP Morgan $15 → $17 Ma
BenzingaMar 27 13:43 ET
No Data
No Data